Biperiden and haloperidol plasma levels and extrapyramidal side effects in schizophrenic patients

被引：5
|
作者：
Meszaros, K
Lenzinger, E
Hornik, K
Schonbeck, G
Hatzinger, R
Langer, G
Sieghart, W
Aschauer, HN
机构：
[1] UNIV VIENNA, HOSP PSYCHIAT, DEPT GEN PSYCHIAT, VIENNA, AUSTRIA
[2] VIENNA UNIV ECON, DEPT STAT, VIENNA, AUSTRIA
[3] VIENNA TECH UNIV, INST STAT & WAHRSCHEINLICHKEITSTHEORIE, VIENNA, AUSTRIA
来源：
NEUROPSYCHOBIOLOGY | 1997年 / 36卷 / 02期
关键词：
biperiden plasma levels; haloperidol plasma levels; relation between dose and plasma levels; extrapyramidal side effects; chronic schizophrenia;
D O I：
10.1159/000119365
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
Anticholinergic drugs such as biperiden are used for the treatment of extrapyramidal side effects (EPS) induced by neuroleptics such as haloperidol. The effects of biperiden and haloperidol plasma levels on EPS were studied in 29 chronically ill schizophrenics. The results show relationships between biperiden dose and biperiden plasma levels (BPL), and between BPL and haloperidol plasma levels (HPL). Neither BPL nor HPL seem to influence EPS.
引用
收藏
页码：69 / 72
页数：4
相关论文
共 50 条
  • [1] Blood levels of reduced haloperidol versus clinical efficacy and extrapyramidal side effects of haloperidol
    Lane, HY
    Lin, HN
    Hu, OYP
    Chen, CC
    Jann, MW
    Chang, WH
    PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 1997, 21 (02): : 299 - 311
  • [2] HALOPERIDOL AND REDUCED HALOPERIDOL PLASMA-LEVELS IN SCHIZOPHRENIC-PATIENTS
    JANN, MW
    ERESHEFSKY, L
    SAKLAD, SR
    RICHARDS, A
    DAVIS, CM
    DRUG INTELLIGENCE & CLINICAL PHARMACY, 1984, 18 (06): : 507 - 507
  • [3] Effects of carbamazepine and valproate on haloperidol plasma levels and on psychopathologic outcome in schizophrenic patients
    Hesslinger, B
    Normann, C
    Langosch, JM
    Klose, P
    Berger, M
    Walden, J
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1999, 19 (04) : 310 - 315
  • [4] RELATION OF PLASMA FLUPHENAZINE LEVELS TO TREATMENT RESPONSE AND EXTRAPYRAMIDAL SIDE-EFFECTS IN FIRST-EPISODE SCHIZOPHRENIC-PATIENTS
    KOREEN, AR
    LIEBERMAN, J
    ALVIR, J
    CHAKOS, M
    LOEBEL, A
    COOPER, T
    KANE, J
    AMERICAN JOURNAL OF PSYCHIATRY, 1994, 151 (01): : 35 - 39
  • [5] EXTRAPYRAMIDAL SIDE-EFFECTS OF CLOZAPINE AND HALOPERIDOL
    KURZ, M
    HUMMER, M
    OBERBAUER, H
    FLEISCHHACKER, WW
    PSYCHOPHARMACOLOGY, 1995, 118 (01) : 52 - 56
  • [6] HALOPERIDOL AND REDUCED HALOPERIDOL PLASMA-LEVELS IN SELECTED SCHIZOPHRENIC-PATIENTS
    ERESHEFSKY, L
    DAVIS, CM
    HARRINGTON, CA
    JANN, MW
    BROWNING, JL
    SAKLAD, SR
    BURCH, NR
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1984, 4 (03) : 138 - 142
  • [7] Risperidone and haloperidol extrapyramidal side effects: clinical study
    Marinkovic, D.
    Totic, S.
    Marjanovic, M.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2013, 23 : S494 - S494
  • [8] Lower plasma levels of haloperidol in smoking than in nonsmoking schizophrenic patients
    Shimoda, K
    Someya, T
    Morita, S
    Hirokane, G
    Noguchi, G
    Yokono, A
    Shibasaki, M
    Takahashi, S
    THERAPEUTIC DRUG MONITORING, 1999, 21 (03) : 293 - 296
  • [9] PLASMA-LEVELS OF NEUROLEPTIC DRUGS AND EXTRAPYRAMIDAL SYMPTOMS IN SCHIZOPHRENIC-PATIENTS
    BLOEINK, M
    BERGENER, M
    HESSE, C
    INTERNATIONAL JOURNAL OF NEUROSCIENCE, 1987, 32 (1-2) : 833 - 833
  • [10] RELATIONSHIPS BETWEEN SERUM LEVELS OF HALOPERIDOL AND PROLACTIN, ANTIPSYCHOTIC EFFECT, AND EXTRAPYRAMIDAL SIDE-EFFECTS
    MOLLER, HJ
    KISSLING, W
    MAURACH, R
    SCHMID, W
    DOERR, P
    PIRKE, K
    VONZERSSEN, D
    PHARMACOPSYCHIATRIA, 1981, 14 (01): : 27 - 34
12345